Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous SCT.
P
P
Dreger
B
B
Glass
B
B
Seyfarth
A
A
Humpe
A
A
Claviez
N
N
von Neuhoff
M
M
Suttorp
R
R
Schoch
N
N
Schmitz
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000592:standards; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000592:standards; D006084:Graft Rejection; D020350:Graft vs Tumor Effect / Q000187:drug effects; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000601:surgery*; D008875:Middle Aged; D016879:Salvage Therapy; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous / Q000379:methods*; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000592:standards
D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine